Abstract
Chronic thromboembolic pulmonary hypertension (CTEPH) is a unique form of pulmonary
hypertension arising from fibrotic obliteration of major pulmonary arteries. Pro-thrombotic
states, large clot burden and impaired dissolution are believed to contribute to the
occurrence and progression of thrombosis after an acute pulmonary embolic event. Recent
data utilizing several models have facilitated the understanding of clot resolution.
This review summarizes current knowledge on pathophysiological mechanisms of major
vessel occlusion in CTEPH.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Thrombosis ResearchAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Update on chronic thromboembolic pulmonary hypertension.Circulation. 2014; 130: 508-518
- Chronic thromboembolic pulmonary hypertension: a distinct disease entity.Eur. Respir. Rev. 2015; 24: 246-252
- Risk factors for chronic thromboembolic pulmonary hypertension.Proc. Am. Thorac. Soc. 2006; 3: 568-570
- Chronic major-vessel thromboembolic pulmonary hypertension.Circulation. 1990; 81: 1735-1743
- Pulmonary vascular lesions occurring in patients with chronic major vessel thromboembolic pulmonary hypertension.Chest. 1993; 103: 685-692
- Pulmonary microvascular disease in chronic thromboembolic pulmonary hypertension.Proc. Am. Thorac. Soc. 2006; 3: 571-576
- Predictors of outcome in chronic thromboembolic pulmonary hypertension.Circulation. 2007; 115: 2153-2158
- 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT).Eur. Respir. J. 2015; 46: 903-975
- High factor VIII (FVIII) levels in venous thromboembolism: role of unbound FVIII.Thromb. Haemost. 2004; 92: 42-46
- Riociguat for the treatment of chronic thromboembolic pulmonary hypertension.N. Engl. J. Med. 2013; 369: 319-329
- Treatment of pulmonary arterial hypertension with targeted therapies.Nat. Rev. Cardiol. 2011; 8: 526-538
- The sGC activator inhibits the proliferation and migration, promotes the apoptosis of human pulmonary arterial smooth muscle cells via the up regulation of plasminogen activator inhibitor-2.Exp. Cell Res. 2015; 332: 278-287
- Soluble guanylate cyclase stimulation prevents fibrotic tissue remodeling and improves survival in salt-sensitive Dahl rats.PLoS One. 2011; 6e21853
- The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats.PLoS One. 2012; 7e43433
- Nitric oxide-independent stimulation of soluble guanylate cyclase reduces organ damage in experimental low-renin and high-renin models.J. Hypertens. 2010; 28: 1666-1675
- Stimulation of the soluble guanylate cyclase (sGC) inhibits fibrosis by blocking non-canonical TGFbeta signalling.Ann. Rheum. Dis. 2015; 74: 1408-1416
- Inhibition of TGF-beta induced lung fibroblast to myofibroblast conversion by phosphodiesterase inhibiting drugs and activators of soluble guanylyl cyclase.Eur. J. Pharmacol. 2007; 572: 12-22
- BAY 41-2272, a direct activator of soluble guanylate cyclase, reduces right ventricular hypertrophy and prevents pulmonary vascular remodeling during chronic hypoxia in neonatal rats.Biol. Neonate. 2006; 90: 135-144
- Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension.Eur. Respir. J. 2008; 32: 881-891
- Risk factors and basic mechanisms of chronic thromboembolic pulmonary hypertension: a current understanding.Eur. Respir. J. 2013; 41: 462-468
- Unilateral chronic thromboembolic pulmonary disease associated with combined inherited thrombophilia.Chest. 2002; 121: 286-289
- High prevalence of elevated clotting factor VIII in chronic thromboembolic pulmonary hypertension.Thromb. Haemost. 2003; 90: 372-376
- Fibrin derived from patients with chronic thromboembolic pulmonary hypertension is resistant to lysis.Am. J. Respir. Crit. Care Med. 2006; 173: 1270-1275
- Abnormally sialylated fibrinogen gamma-chains in a patient with chronic thromboembolic pulmonary hypertension.Thromb. Res. 2007; 119: 257-259
- High prevalence of dysfibrinogenemia among patients with chronic thromboembolic pulmonary hypertension.Blood. 2009; 114: 1929-1936
- Non-OO blood type influences the risk of recurrent venous thromboembolism. a cohort study.Thromb. Haemost. 2013; 110: 1172-1179
- Thrombotic risk factors in pulmonary hypertension.Eur. Respir. J. 2000; 15: 395-399
- Hereditary and acquired thrombotic risk factors for chronic thromboembolic pulmonary hypertension.Blood Coagul. Fibrinolysis. 2010; 21: 201-206
- Kinetics of factor VIII-von Willebrand factor association.Blood. 1996; 87: 1809-1816
- ABO blood group determines plasma von Willebrand factor levels: a biologic function after all?.Transfusion. 2006; 46: 1836-1844
- The relationship between ABO histo-blood group, factor VIII and von Willebrand factor.Transfus. Med. 2001; 11: 343-351
- Functional effects of the ABO locus polymorphism on plasma levels of von Willebrand factor, factor VIII, and activated partial thromboplastin time.Arterioscler. Thromb. Vasc. Biol. 2000; 20: 2024-2028
- The effect of ABO blood group on the diagnosis of von Willebrand disease.Blood. 1987; 69: 1691-1695
- Factor VIII and factor IX in a twin population. Evidence for a major effect of ABO locus on factor VIII level.Am. J. Hum. Genet. 1985; 37: 89-101
- Factor VIII levels and blood group antigens.Thromb. Haemost. 1983; 50: 757
- Major blood group antigens—determinant of factor VIII levels in blood?.Thromb. Haemost. 1984; 51: 414
- Genotype at the secretor blood group locus is a determinant of plasma von Willebrand factor level.Br. J. Haematol. 2002; 116: 350-356
- A shorter von Willebrand factor survival in O blood group subjects explains how ABO determinants influence plasma von Willebrand factor.Blood. 2008; 111: 3540-3545
- High prevalence of elevated factor VIII levels in patients referred for thrombophilia screening: role of increased synthesis and relationship to the acute phase reaction.Thromb. Haemost. 1997; 77: 825-828
- High plasma levels of factor VIII and the risk of recurrent venous thromboembolism.N. Engl. J. Med. 2000; 343: 457-462
- Thrombotic microangiopathies: towards a pathophysiology-based classification.Cardiovasc. Hematol. Disord. Drug Targets. 2009; 9: 36-50
- Polymorphisms and mutations in vWF and ADAMTS13 genes and their correlation with plasma levels of FVIII and vWF in patients with deep venous thrombosis.Clin. Appl. Thromb. Hemost. 2011; 17: 514-518
- Increased ADAMTS13 activity in patients with venous thromboembolism.Thromb. Res. 2012; 130: 889-893
- Primary antiphospholipid syndrome and pulmonary hypertension.Curr. Pharm. Des. 2014; 20: 545-551
- Lupus anticoagulant, heparin use, and thrombocytopenia in patients with chronic thromboembolic pulmonary hypertension: a preliminary report.Am. J. Med. 1995; 99: 392-396
- Risk factors for chronic thromboembolic pulmonary hypertension.Eur. Respir. J. 2009; 33: 325-331
- Fibrin resistance to lysis in patients with pulmonary hypertension other than thromboembolic.Am. J. Respir. Crit. Care Med. 2010; 181: 992-996
- Fibrinogen Aalpha Thr312Ala polymorphism is associated with chronic thromboembolic pulmonary hypertension.Eur. Respir. J. 2008; 31: 736-741
- Fibrinogen Alpha Thr312Ala polymorphism specifically contributes to chronic thromboembolic pulmonary hypertension by increasing fibrin resistance.PLoS One. 2013; 8e69635
- Association of the alpha-fibrinogen Thr312Ala polymorphism with poststroke mortality in subjects with atrial fibrillation.Circulation. 1999; 99: 2423-2426
- Alpha-fibrinogen Thr312Ala polymorphism and venous thromboembolism.Blood. 2000; 96: 1177-1179
- Beta fibrinogen gene polymorphisms are associated with plasma fibrinogen and coronary artery disease in patients with myocardial infarction. The ECTIM study. Etude Cas-Temoins sur l'Infarctus du Myocarde.Circulation. 1996; 93: 440-449
- Endogenous fibrinolytic system in chronic large-vessel thromboembolic pulmonary hypertension.Circulation. 1992; 86: 1241-1248
- Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis.Blood. 2005; 105: 1102-1105
- Chronic pulmonary thromboembolism in dogs treated with tranexamic acid.Circulation. 1991; 83: 1371-1379
- Why acute pulmonary embolism becomes chronic thromboembolic pulmonary hypertension: clinical and genetic insights.Curr. Opin. Pulm. Med. 2013; 19: 422-429
- Expression of type 1 plasminogen activator inhibitor in chronic pulmonary thromboemboli.Circulation. 1994; 89: 2715-2721
- Impaired fibrinolysis in angiographically documented coronary artery disease.Adv. Hematol. 2015; 2015: 214680
- Thrombin activatable fibrinolysis inhibitor (TAFI)—how does thrombin regulate fibrinolysis?.Ann. Med. 2006; 38: 378-388
- Thrombin activatable fibrinolysis inhibitor and an antifibrinolytic pathway.Arterioscler. Thromb. Vasc. Biol. 2000; 20: 2511-2518
- Enhancement of rabbit jugular vein thrombolysis by neutralization of factor XI. In vivo evidence for a role of factor XI as an anti-fibrinolytic factor.J. Clin. Invest. 1998; 101: 10-14
- An inhibitor of activated thrombin-activatable fibrinolysis inhibitor potentiates tissue-type plasminogen activator-induced thrombolysis in a rabbit jugular vein thrombolysis model.Thromb. Res. 2000; 98: 333-342
- Inducible carboxypeptidase activity. A role in clot lysis in vivo.Circulation. 1996; 93: 1328-1330
- Activated human protein C prevents thrombin-induced thromboembolism in mice. Evidence that activated protein c reduces intravascular fibrin accumulation through the inhibition of additional thrombin generation.J. Clin. Invest. 1998; 101: 667-676
- Deficiency in thrombin-activatable fibrinolysis inhibitor (TAFI) protected mice from ferric chloride-induced vena cava thrombosis.J. Thromb. Thrombolysis. 2007; 23: 41-49
- Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis.Blood. 2000; 95: 2855-2859
- Pulmonary hypertension after splenectomy: a consequence of loss of the splenic filter or is there something more?.Thorax. 2005; 60: 983-984
- Medical conditions increasing the risk of chronic thromboembolic pulmonary hypertension.Thromb. Haemost. 2005; 93: 512-516
- Splenectomy and chronic thromboembolic pulmonary hypertension.Thorax. 2005; 60: 1031-1034
- Membrane phospholipid asymmetry in human thalassemia.Blood. 1998; 91: 3044-3051
- Splenectomy changes the pattern of cytokine production in beta-thalassemic patients.Cytokine. 2006; 35: 253-257
- Chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry.Circulation. 2011; 124: 1973-1981
- Prognostic and aetiological factors in chronic thromboembolic pulmonary hypertension.Eur. Respir. J. 2009; 33: 332-338
- Immune restoration in children after partial splenectomy.Immunobiology. 1993; 188: 370-378
- Immune response after splenectomy.Lancet. 1978; 1: 178-181
- Prevention and management of overwhelming postsplenectomy infection—an update.Crit. Care Med. 1999; 27: 836-842
- Splenectomy is modifying the vascular remodeling of thrombosis.J. Am. Heart Assoc. 2014; 3e000772
- The role of neovascularisation in the resolution of venous thrombus.Thromb. Haemost. 2005; 93: 801-809
- Platelet endothelial cell adhesion molecule 1 deficiency misguides venous thrombus resolution.Blood. 2013; 122: 3376-3384
- Defective angiogenesis delays thrombus resolution: a potential pathogenetic mechanism underlying chronic thromboembolic pulmonary hypertension.Arterioscler. Thromb. Vasc. Biol. 2014; 34: 810-819
- Role for staphylococci in misguided thrombus resolution of chronic thromboembolic pulmonary hypertension.Arterioscler. Thromb. Vasc. Biol. 2008; 28: 678-684
- Macrophage-derived growth factors in wound healing: regulation of growth factor production by the oxygen microenvironment.Am. Rev. Respir. Dis. 1989; 140: 1108-1111
- Vascular endothelial growth factor and basic fibroblast growth factor are found in resolving venous thrombi.J. Vasc. Surg. 2000; 32: 988-996
- Interleukin-8 administration enhances venous thrombosis resolution in a rat model.J. Surg. Res. 2001; 99: 84-91
- Vascular endothelial growth factor naked DNA gene transfer enhances thrombus recanalization and resolution.J. Vasc. Surg. 2005; 42: 1183-1189
- Adenovirus-mediated VEGF gene therapy enhances venous thrombus recanalization and resolution.Arterioscler. Thromb. Vasc. Biol. 2008; 28: 1753-1759
- Vascular endothelial growth factor enhances venous thrombus recanalisation and organisation.Thromb. Haemost. 2003; 89: 169-176
- Contribution of inflammation and impaired angiogenesis to the pathobiology of chronic thromboembolic pulmonary hypertension.Eur. Respir. J. 2015; 46: 431-443
- Antiangiogenic therapy inhibits venous thrombus resolution.Arterioscler. Thromb. Vasc. Biol. 2014; 34: 565-570
- Suppression of angiogenic response in local vein wall is associated with reduced thrombus resolution.Thromb. Res. 2014; 134: 682-685
- Deep vein thrombosis resolution is not accelerated with increased neovascularization.J. Vasc. Surg. 2004; 40: 536-542
- Angiogenesis: a dynamic balance of stimulators and inhibitors.Thromb. Haemost. 1997; 78: 672-677
- Basic and therapeutic aspects of angiogenesis.Cell. 2011; 146: 873-887
- Angiogenesis and its therapeutic opportunities.Mediat. Inflamm. 2013; 2013: 127170
- Notch signaling: cell fate control and signal integration in development.Science. 1999; 284: 770-776
- Notch signaling in vertebrate development and disease.Mol. Cell. Neurosci. 1997; 9: 103-108
- The role of notch in modeling and maintaining the vasculature.Can. J. Physiol. Pharmacol. 2005; 83: 14-23
- VEGF and notch in tip and stalk cell selection.Cold Spring Harb. Perspect. Med. 2013; 3: a006569
- Angiogenesis: a team effort coordinated by notch.Dev. Cell. 2009; 16: 196-208
- Dynamics of endothelial cell behavior in sprouting angiogenesis.Curr. Opin. Cell Biol. 2010; 22: 617-625
- Studies on the vasculogenesis in rat cerebral cortex.Anat. Rec. 1989; 224: 355-364
- Endothelial signalling by the Notch ligand Delta-like 4 restricts angiogenesis.Development. 2007; 134: 839-844
- Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis.Nature. 2007; 445: 776-780
- Regulation of vascular morphogenesis by Notch signaling.Genes Dev. 2007; 21: 2511-2524
- Notch signalling limits angiogenic cell behaviour in developing zebrafish arteries.Nature. 2007; 445: 781-784
- The Notch ligand Delta-like 4 negatively regulates endothelial tip cell formation and vessel branching.Proc. Natl. Acad. Sci. U. S. A. 2007; 104: 3225-3230
- Notch3 signaling promotes the development of pulmonary arterial hypertension.Nat. Med. 2009; 15: 1289-1297
- Notch signaling change in pulmonary vascular remodeling in rats with pulmonary hypertension and its implication for therapeutic intervention.PLoS One. 2012; 7e51514
- Late prognosis of acute pulmonary embolism.N. Engl. J. Med. 1973; 289: 55-58
- Pulmonary embolism.JAMA. 1969; 207: 1505-1507
- Factors influencing the restoration of blood flow following pulmonary embolization as determined by angiography and scanning.Circulation. 1968; 38: 1116-1126
- Pathology of pulmonary thromboembolism.Chest. 1995; 107: 10S-17S
- The effect of matrix metalloproteinase 2 and matrix metalloproteinase 2/9 deletion in experimental post-thrombotic vein wall remodeling.J. Vasc. Surg. 2013; 58 (e2): 1375-1384
- Neutropenia impairs venous thrombosis resolution in the rat.J. Vasc. Surg. 2003; 38: 1090-1098
- Neutrophils and deep venous thrombosis.Haemostasis. 1993; 23: 127-140
- The myofibroblast in pulmonary fibrosis.Chest. 2002; 122: 286S-289S
- Role of endothelial-mesenchymal transition (EndoMT) in the pathogenesis of fibrotic disorders.Am. J. Pathol. 2011; 179: 1074-1080
- Endothelial-to-mesenchymal transition contributes to cardiac fibrosis.Nat. Med. 2007; 13: 952-961
- Fibrocytes contribute to the myofibroblast population in wounded skin and originate from the bone marrow.Exp. Cell Res. 2005; 304: 81-90
- Characterization of myofibroblasts in chronic thromboembolic pulmonary hypertension.Int. J. Cardiol. 2012; 159: 119-127
- Surgical pathology of pulmonary thromboendarterectomy: a study of 54 cases from 1990 to 2001.Hum. Pathol. 2003; 34: 1290-1298
- TGF-beta signaling in vascular biology and dysfunction.Cell Res. 2009; 19: 116-127
- TGF-beta1-mediated fibroblast-myofibroblast terminal differentiation-the role of Smad proteins.Exp. Cell Res. 2003; 282: 90-100
- Normal and pathologic soft tissue remodeling: role of the myofibroblast, with special emphasis on liver and kidney fibrosis.Lab. Investig. 2003; 83: 1689-1707
- Transforming growth factor beta-induced endothelial-to-mesenchymal transition: a switch to cardiac fibrosis?.Trends Cardiovasc. Med. 2008; 18: 293-298
- The serum concentration of active transforming growth factor-beta is severely depressed in advanced atherosclerosis.Nat. Med. 1995; 1: 74-79
- Transforming growth factor-beta-induced protein (TGFBIp/beta ig-h3) activates platelets and promotes thrombogenesis.Blood. 2009; 114: 5206-5215
- Inhibition of transforming growth factor-beta restores endothelial thromboresistance in vein grafts.J. Vasc. Surg. 2011; 54 (e1): 1117-1123
- From thrombosis to fibrosis in chronic thromboembolic pulmonary hypertension.Thromb. Haemost. 2017; 117: 769-783
- In vivo and post mortem dissolution rates of pulmonary emboli and venous thrombi in the dog.Circulation. 1973; 48: 170-178
- Suppression of thrombolysis in a canine model of pulmonary embolism.Circulation. 1994; 90: 3091-3097
- Endothelin mediates pulmonary vascular remodelling in a canine model of chronic embolic pulmonary hypertension.Eur. Respir. J. 2000; 15: 640-648
- Factors contributing to increased vascular fibrinolytic activity in mongrel dogs.Circulation. 1993; 87: 1990-2000
- Recruitment of labelled monocytes by experimental venous thrombi.Thromb. Haemost. 2001; 85: 1018-1024
- Neovascularization during venous thrombosis organization: a preliminary study.J. Vasc. Surg. 1999; 30: 885-892
- Deep vein thrombosis resolution is modulated by monocyte CXCR2-mediated activity in a mouse model.Arterioscler. Thromb. Vasc. Biol. 2004; 24: 1130-1137
- Staging deep venous thrombosis using ultrasound elasticity imaging: animal model.Ultrasound Med. Biol. 2004; 30: 1385-1396
- Venous thrombosis-associated inflammation and attenuation with neutralizing antibodies to cytokines and adhesion molecules.Arterioscler. Thromb. Vasc. Biol. 1995; 15: 258-268
- Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo.J. Exp. Med. 2012; 209: 819-835
- Piglet model of chronic pulmonary hypertension.Pulm. Circ. 2013; 3: 908-915
Article info
Publication history
Published online: June 14, 2017
Accepted:
June 8,
2017
Received in revised form:
June 2,
2017
Received:
March 31,
2017
Identification
Copyright
© 2017 Elsevier Ltd. All rights reserved.
